Herantis Pharma announces successful completion of six-month GLP toxicology study of HER-096
Key step achieved in advancing HER-096 towards Phase 2 efficacy trial Espoo, Finland, 26 November 2025: Herantis Pharma Plc (“Herantis”),...
Year: 2025
CG Oncology Announces New Board Member and Board Transition
- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE...
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
NEW HAVEN, Conn., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new...
Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
BOSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Adam Crystal, M.D., Ph.D., President...
Picard Medical to Present the Next Generation Fully Implantable SynCardia Total Artificial Heart at ISMCS 2025
TUCSON, Ariz., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company...
Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
RAMAT GAN, Israel, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company...
Scilex Holding Company Announces Closing of Previously Announced Second Tranche Investment in Datavault AI Inc., Completing Its Two-Tranche Equity Financing in Datavault AI Inc.
Scilex closed the second tranche, purchasing a pre-funded warrant exercisable for 263,914,094 shares of Datavault AI Inc. (Nasdaq: DVLT; “Datavault...
Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage...
Tangram Therapeutics Submits Clinical Trial Application for Phase 1/2 Study of TGM-312, a Novel Investigational RNAi MASH Candidate
The Company expects to initiate first-in-human study in early 2026, with initial data anticipated H2 2026 Clinical Trial Application (CTA)...
Nyxoah’s Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule
Nyxoah’s Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule Assignment to New Technology APC 1580 is...
Galapagos Receives Transparency Notifications from Bank of America
Mechelen, Belgium; November 26, 2025, 07:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from...
Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate
Antibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster doseNo...
Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference
Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference Schlieren (Zürich), Switzerland, November 26, 2025 – Kuros...
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia
– Prescription Drug User Fee Act (PDUFA) goal date extended by three months to February 28, 2026 COPENHAGEN, Denmark, Nov....
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
KOMZIFTI, the first and only once-daily FDA-approved menin inhibitor for R/R NPM1-mutated AML, is now commercially available in the United...
BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis
The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift...
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference
EMERYVILLE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company...
Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting
NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG),...
Anaptys Announces Participation in December Investor Conferences
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...
Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference
DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing,...